Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 60Lung Neoplasms 38Melanoma 22Ovarian Neoplasms 20Breast Neoplasms 18Mesothelioma, Malignant 13Colorectal Neoplasms 13Pancreatic Neoplasms 12Neoplasm Metastasis 12Small Cell Lung Carcinoma 11Triple Negative Breast Neoplasms 10Carcinoma, Renal Cell 10Neoplasms 9Mesothelioma 9Stomach Neoplasms 8Sarcoma 8Thymoma 7Carcinoma, Hepatocellular 7Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Merkel Cell 6Esophageal Neoplasms 5Carcinoma, Transitional Cell 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Sarcoma, Synovial 4Multiple Myeloma 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Ovarian Epithelial 4

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1carboxyamido-triazole 1aldesleukin 1Thalidomide 1Paclitaxel 1Fentanyl 1Docetaxel 1Cyclophosphamide 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × Cyclophosphamide × Thoracic × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡